The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells.
作者信息
Mohr Brigitte, Oelschlaegel Uta, Thiede Christian, Stewart Michelle Meredyth, Ehninger Gerhard, Platzbecker Uwe
出版信息
Haematologica. 2009 Mar;94(3):430-1. doi: 10.3324/haematol.13865. Epub 2009 Jan 30.
Abstract
摘要
相似文献
1
The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells.
Haematologica. 2009 Mar;94(3):430-1. doi: 10.3324/haematol.13865. Epub 2009 Jan 30.
2
Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.
Haematologica. 2011 Feb;96(2):319-22. doi: 10.3324/haematol.2010.026658. Epub 2010 Nov 25.
3
Persistent malignant stem cells in del(5q) myelodysplasia in remission.
N Engl J Med. 2010 Sep 9;363(11):1025-37. doi: 10.1056/NEJMoa0912228.
4
Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
Haematologica. 2010 Mar;95(3):406-14. doi: 10.3324/haematol.2009.010876. Epub 2009 Sep 22.
5
Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.
Haematologica. 2013 Mar;98(3):409-13. doi: 10.3324/haematol.2012.066068. Epub 2012 Aug 28.
6
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Expert Rev Anticancer Ther. 2010 Oct;10(10):1663-72. doi: 10.1586/era.10.135.
7
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
J Hematol Oncol. 2012 Mar 5;5:4. doi: 10.1186/1756-8722-5-4.
8
Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
Leuk Res. 2011 Sep;35(9):e175-6. doi: 10.1016/j.leukres.2011.05.020. Epub 2011 Jun 11.
9
Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Cancer Genet Cytogenet. 2008 Dec;187(2):101-11. doi: 10.1016/j.cancergencyto.2008.08.002.
10
Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
Leuk Lymphoma. 2010 Oct;51(10):1941-3. doi: 10.3109/10428194.2010.506567.
引用本文的文献
1
Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study.
Haematologica. 2010 Mar;95(3):398-405. doi: 10.3324/haematol.2009.012773. Epub 2009 Oct 8.
本文引用的文献
1
Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis.
Haematologica. 2008 Jul;93(7):967-72. doi: 10.3324/haematol.13377.
2
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
N Engl J Med. 2006 Oct 5;355(14):1456-65. doi: 10.1056/NEJMoa061292.
3
Efficacy of lenalidomide in myelodysplastic syndromes.
N Engl J Med. 2005 Feb 10;352(6):549-57. doi: 10.1056/NEJMoa041668.
4
Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells.
Ann Hematol. 2002;81 Suppl 2:S27-8.
5
Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation.
Leukemia. 2001 Dec;15(12):1976-85. doi: 10.1038/sj.leu.2402311.
Zotero 插件